Work

Glucagon-like peptide-1 and dual/triple receptor agonists in the treatment of metabolic dysfunction-associated steatotic liver disease: advances in mechanistic research

Year: 2026

Type: article

Abstract: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has emerged as a prevalent and severe global hepatic disorder, necessitating the development of effective therapeutic strategies. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), along with glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCG) dual or triple receptor agonists that modulate multiple metabolic pathways, have attracted significant scientific interest due to their multifaceted roles in metabolic regulation. This review provides a comprehensive overview of the mechanistic insights into the effects of GLP-1RAs and dual or triple receptor agonists on the pathophysiology of MASLD, with a focus on hepatic lipid metabolism, inflammatory responses, and fibrosis progression.

Source: Frontiers in Medicine

DOI: 10.3389/fmed.2026.1763185

Authors: Xinyi Lu, Li Yang

Institutions: Zhujiang Hospital, Southern Medical University

Language: English

Topic: Liver Disease Diagnosis and Treatment

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801